Detail page

Knowledge Web

Person

Marc-Steffen Raab (1973-)

Arzt

Name	Marc-Steffen Raab
Time	1973- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Dr. med.
Profession	Arzt (characteristic profession)
Variant	Marc Raab Marc S. Raab M. S. Raab Marc Steffen Raab
Related	Universitätsklinikum Heidelberg. Zentrum für Innere Medizin (09/2000-) Universität Heidelberg. Medizinische Fakultät (Lehrbeauftragter) (02/2015-12/2017)
Further information	Leitung des klinischen Studienprogramms (Phase I/II) des Myelomzentrums am Universitätsklinikum und dem Nationalen Centrum für Tumorerkrankungen, Universität Heidelberg
Record type	Person
GND-Identifier	124052460
Record ID	124052460
Involved in show all Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany Real-world analysis of teclistamab in 123 RRMM patients from Germany A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders Identification of novel genetic loci for risk of multiple myeloma by functional annotation Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells Vergleichende Analyse von Therapieansprechen und -toxizität der Hochdosischemotherapie und autologen Stammzelltransplantation in der Erstlinien- und Rezidivtherapie von Patienten mit Multiplem Myelom Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Novel immunotherapies in multiple myeloma – chances and challenges Selective elimination of immunosuppressive T cells in patients with multiple myeloma FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells Spectrum and functional validation of PSMB5 mutations in multiple myeloma Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma Functional characterizations of BRAF mutations in multiple myeloma Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology Das immunogene Glykoprotein des humanen Herpesvirus 8 (HHV-8) : ein neues serologisches Nachweisverfahren

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Marc-Steffen Raab (1973-)

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany

Real-world analysis of teclistamab in 123 RRMM patients from Germany

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations

High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Identification of novel genetic loci for risk of multiple myeloma by functional annotation

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells

Vergleichende Analyse von Therapieansprechen und -toxizität der Hochdosischemotherapie und autologen Stammzelltransplantation in der Erstlinien- und Rezidivtherapie von Patienten mit Multiplem Myelom

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Novel immunotherapies in multiple myeloma – chances and challenges

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

Functional characterizations of BRAF mutations in multiple myeloma

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology

Das immunogene Glykoprotein des humanen Herpesvirus 8 (HHV-8) : ein neues serologisches Nachweisverfahren